Although DNA-based approaches for KD mutation determination have the disadvantage of amplifying ABL1 from (i) non-rearranged ABL1 allele of tumor cells and (ii) the ABL1 gene of non-rearranged healthy cells, they might better represent the clonal burden and dynamics of the emerging resistant clones. The gene discussed is ABL1; the disease is neoplasm.